Effect of Amifostine on the Acute Toxicity Reduction After Megachemo-therapy in Children
Authors:
J. Válková; J. Staňková; P. Kavan; E. Kabíčková; P. Gajdoš; J. Koutecký
Authors‘ workplace:
Klinika dětské onkologie 2. LF UK a FNM, Praha
Published in:
Čas. Lék. čes. 2002; : 316-319
Category:
Overview
Background.
Amifostine (WR-2721,Ethyol)is a chemoprotective agent.There is little experiences with amifos-tine application in megachemotherapy in children.We evaluated amifostine effect on the reduction of the acutetoxicity.Methods and Results.Retrospective comparison of patients who received amifostine with the control group (72vs.72).Amifostine 750 mg/m2was given 15 minute before cytostatic dose and regularly each eight hours if weadministered cytostatics continuously.Megachemotherapy schedule included melfalan,carboplatin,cyklophospha-mid,vepesid,busulfan,thiotepa and karmustin.Type of graft:peripheral stem cells 56 vs.29,bone marrow 8 vs.30,combination 8 vs.13.Nonhematological toxicity:mucositis p=0.047,hepatotoxicity p
Key words:
amifostine,megachemotherapy,acute toxicity reduction.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Genetic Syndromology –an Introduction to a Series of Papers
- Effect of Amifostine on the Acute Toxicity Reduction After Megachemo-therapy in Children
- Ethical,Psycho-social,Legislative and Economical Aspects of the Surgical Treatment of HypoplasticLeft Heart Syndrome
- Hyperbaric Oxygen Therapy in Management of Sport Injuries